Drug intelligence / Profile preview

clade C gp140

Development stage
Discontinued
Lead developer
Johnson & Johnson
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

Clade C gp140 is a recombinant protein immunogen derived from the envelope glycoprotein (Env) of HIV-1 subtype (clade) C. It consists of the extracellular portions of the viral envelope proteins gp120 and part of gp41, engineered to form a soluble trimer that mimics the native structure on the virus surface. Clade C is globally significant as it represents the most prevalent HIV-1 subtype in regions such as southern Africa and India. The primary mechanism involves eliciting an immune response—specifically neutralizing antibodies—against diverse strains of HIV-1 by presenting conserved epitopes in their native-like conformation. Clade C gp140 has been evaluated as a vaccine antigen in preclinical models and early-phase clinical trials for its ability to induce binding and neutralizing antibody responses against multiple HIV subtypes[2][3]. It is typically administered with adjuvants or as part of heterologous prime/boost regimens.

Other names
HIV-1 clade C gp140HIV1 clade C gp140HIV 1 clade C gp140HIV-1 Env clade C gp140HIV1 Env clade C gp140HIV 1 Env clade C gp140subtype C gp140
02

Targets

CD4 (T lymphocyte surface antigen)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on clade C gp140.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clade C gp140.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call